Crawford D J, George W D, Smith D C, Stewart M, Paul J, Leake R E
Department of Surgery, Western Infirmary, Scotland.
Oncology. 1994 Oct;51 Suppl 1:13-8. doi: 10.1159/000227410.
A cyclical, sequential combination of tamoxifen and megestrol acetate (group B) was compared with conventional therapy (tamoxifen alone, group A) in 261 breast cancer patients. There was no statistically significant difference between groups for overall response rate (complete+partial response: group A, 35.8%, group B, 40.8%; p = 0.505) or for median response duration in responders (group A, 128 weeks, group B, 136 weeks; p = 0.488). Median survival from randomization was longer in those patients receiving sequential therapy (group A, 90 weeks, group B, 134 weeks) with a significantly lower relative death rate (group B/group A = 0.67; p = 0.011). This survival benefit appears to be due to a delay in progression among nonresponders in the sequential therapy group.
在261例乳腺癌患者中，将他莫昔芬与醋酸甲地孕酮的周期性序贯联合治疗（B组）与传统治疗（单纯他莫昔芬，A组）进行了比较。两组的总缓解率（完全缓解+部分缓解：A组为35.8%，B组为40.8%；p = 0.505）或缓解者的中位缓解持续时间（A组为128周，B组为136周；p = 0.488）无统计学显著差异。接受序贯治疗的患者自随机分组后的中位生存期更长（A组为90周，B组为134周），相对死亡率显著更低（B组/A组 = 0.67；p = 0.011）。这种生存获益似乎是由于序贯治疗组中无反应者的疾病进展延迟所致。
